Physician profile
Ferhad Ahmad
NPI 1831484930
$1,367.41
in general payments reported to CMS, 2019-2025
12 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $149 · 2021: $111 · 2022: $418 · 2023: $207 · 2024: $66.01 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $441.52 | 2021-2025 | Vraylar |
| Bausch Health US, LLC | $242.56 | 2020-2025 | Aplenzin |
| Lundbeck LLC | $221.38 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.63 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $104.60 | 2019-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $89.28 | 2019-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $54.44 | 2022 | |
| Alkermes, INC. | $23.80 | 2023 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $23.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.15 | 2025 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $16.21 | 2023 | Hetlioz, Fanapt |
| Allergan, INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferhad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.